Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Alkermes plc

Alkermes plc (ALKS) Stock Overview

Explore Alkermes plc’s financial performance, market position, analyst ratings, and future outlook.

ALKS●NASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$47.89
$1.42(3.06%)
U.S. Market opens in 4h 14m

Alkermes plc (ALKS)

Meyka AI Score

Z

Key Financials

Market Cap8B
P/E Ratio15864.70
EPS (TTM)$0.95
ROE-0.00%
Fundamental Analysis

AI Price Forecasts

1 Month$43.21
3 Months$54.29
1 Year Target$44.42

ALKS Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Alkermes plc (NASDAQ: ALKS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Alkermes plc's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of ALKS on the NASDAQ shows an RSI of 67.74, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $44.42 for the NASDAQ listing.

Key metrics behind Alkermes plc's NASDAQ-traded stock include a P/E ratio of 15864.70 and a market capitalization of 8B. Combined with our AI analysis, these give both institutional and retail investors a clear view of ALKS on the NASDAQ.

Price Performance (NASDAQ: ALKS)

1-Day Change
3.06%
5-Day Change
8.37%
1-Month Change
17.93%
3-Month Change
-2.68%
6-Month Change
35.02%
Year-to-Date (YTD) Change
71.16%
1-Year Change
41.64%
3-Year Change
99.71%
5-Year Change
95.31%
All-Time (Max) Change
770.73%

Contact Information

http://www.alkermes.com
353 1 772 8000
Connaught House, Dublin, DU, D04 C5Y6

Company Facts

20,500 Employees
IPO DateJul 16, 1991
CountryIE
Actively Trading

Frequently Asked Questions